Compare AZI & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AZI | SNTI |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 5.7M |
| IPO Year | 2023 | 2021 |
| Metric | AZI | SNTI |
|---|---|---|
| Price | $0.55 | $2.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $445.50 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 05-29-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $127.27 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.03 | $0.09 |
| 52 Week High | $7.00 | $57.60 |
| Indicator | AZI | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 40.63 | 68.59 |
| Support Level | $0.27 | $0.15 |
| Resistance Level | $0.89 | $7.00 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | 0.02 | 0.39 |
| Stochastic Oscillator | 15.56 | 87.54 |
Autozi Internet Technology (Global) Ltd provides high-quality, affordable, and professional one-stop automotive products and services through online and offline channels in China. Leveraging its online supply chain cloud platform, SaaS platforms, and the network of MBS stores, it has established an ecosystem of lifecycle automotive services by connecting automotive manufacturers, auto parts manufacturers, and insurance companies with MBS stores and various automotive owners. Its business segments include new car sales, auto parts and auto accessories sales, and automotive insurance-related services. The majority of revenue is from the auto parts & auto accessories sales.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).